Is PTLA Sell-Off An Overreaction?
On Thursday, Portola Pharmaceuticals (PTLA) dropped almost 30% after the company’s Phase III study of extended-duration betrixaban failed to achieve primary endpoint in first cohort. The study was designed to assess the relative risk of the two therapies as measured by a composite endpoint of ultrasound-detected (asymptomatic) proximal deep venous thrombosis (DVT), symptomatic DVT, non-fatal pulmonary…